Lingo is a recently discovered "co-receptor" with Nogo receptors on axons and blockade of the Lingo receptor also blocks Nogo receptors. Discovered by scientists at Biogen, this represents a promising therapeutic approach to stimulating regeneration in spinal cord injury. For example, this is one of the treatment approaches that we are very interested in testing in ChinaSCINet. Biogen is a sponsor and supporter of the network. This research in this paper as done in part at Hong Kong University.

[*] Ji B, Li M, Wu WT, Yick LW, Lee X, Shao Z, Wang J, So KF, McCoy JM, Blake Pepinsky R, Mi S and Relton JK (2006). LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci LINGO-1 is a CNS-specific protein and a functional component of the NgR1/p75/LINGO-1 and NgR1/TAJ(TROY)/LINGO-1 signaling complexes that mediate inhibition of axonal outgrowth. These receptor complexes mediate the axonal growth inhibitory effects of Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein (OMgp) via RhoA activation. Soluble LINGO-1 (LINGO-1-Fc), which acts as an antagonist of these pathways by blocking LINGO-1 binding to NgR1, was administered to rats after dorsal or lateral hemisection of the spinal cord. LINGO-1-Fc treatment significantly improved functional recovery, promoted axonal sprouting and decreased RhoA activation and increased oligodendrocyte and neuronal survival after either rubrospinal or corticospinal tract transection. These experiments demonstrate an important role for LINGO-1 in modulating axonal outgrowth in vivo and that treatment with LINGO-1-Fc can significantly enhance recovery after spinal cord injury. Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA 02142, USA.